Alexion Pharmaceuticals Stock News

Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.

Apellis: Potential Headache For Alexion

Alexion's (ALXN) growth prospects look strong for 2020 as Soliris maintains momentum and Ultomiris gains further traction.

Alexion (ALXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

In the latest trading session, Alexion Pharmaceuticals (ALXN) closed at $108.15, marking a +0.75% move from the previous day.

With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.

The short interest data are out for the most recent settlement date, December 13. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential

P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.

ALXN vs. HZNP: Which Stock Is the Better Value Option?

With 2019 fading fast and 2020 rapidly approaching, investors are having to reflect on where the markets started out this year and where they are likely going in in the year ahead.

Biotech Stock Outlook: M&A Activity Retains Growth Streak

Both of these drugmakers have solid portfolios and treatment pipelines, but savvy investors will find good reason to favor one over the other.

P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.

Alexion (ALXN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Investing in stocks based on value analysis is generally considered one of the best practices. In value investing, investors pick stocks that are usually cheap but fundamentally sound.